RT Journal Article
SR Electronic
T1 PD-L1 as a Biomarker for the Efficacy of Durvalumab in Stage III EGFR Mutant NSCLC
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 4505
OP 4516
DO 10.21873/anticanres.17279
VO 44
IS 10
A1 KIM, INSU
A1 CHOI, SUN HA
A1 LEE, SHIN YUP
A1 YOO, SEUNG SOO
A1 PARK, JI EUN
A1 SHIN, KYEONG-CHEOL
A1 JANG, JONG GEOL
A1 HONG, KYUNG SOO
A1 KWON, YONG SHIK
A1 PARK, SUN HYO
A1 CHOI, KEUM-JU
A1 JUNG, CHI YOUNG
A1 KIM, MI-HYUN
A1 KIM, SOO HAN
A1 SEOL, HEE YUN
A1 KIM, JEHUN
A1 PARK, JIN-HAN
A1 KIM, TAE HOON
A1 EOM, JUNG SEOP
A1 AHN, JUNE HONG
YR 2024
UL http://ar.iiarjournals.org/content/44/10/4505.abstract
AB Background/Aim: Durvalumab consolidation is less effective in patients with epidermal growth factor receptor mutant (EGFR M+) NSCLC. Studies of durvalumab on EGFR M+ NSCLC as an expression of programmed death-ligand 1 (PD-L1) expression are limited. The purpose of this study was to determine the effect of durvalumab on PD-L1 expression in EGFR M+ patients. Patients and Methods: This study included 249 unresectable stage III NSCLC patients treated with durvalumab. The primary outcome was progression-free survival (PFS). Cox multivariate analysis was performed based on EGFR and PD-L1 statuses: EGFR M−, PD-L1 ≥50% (cohort A); EGFR M−, PD-L1 <50% (cohort B); EGFR M+, PD-L1 ≥50% (cohort C); and EGFR M+, PD-L1 <50% (cohort D). Results: Overall, 31 of 249 (12.4%) and 218 of the 249 (87.6%) patients had EGFR M+ and EGFR M− NSCLC, respectively. Median PFSs and OSs did not differ (PFS: 16.6 vs. 18.7 months, p=0.591; OS: 37.4 vs. 35.7 months, p=0.271). Median PFS of cohort A did not significantly differ from the median PFSs of cohorts B and C, but it was significantly longer than the median PFS of cohort D (23.7 vs. 15.2 months, p=0.045). Cox multivariate analysis revealed that cohort D exhibited a worse PFS (adjusted hazard ratio=2.27, 95% confidence interval=1.11-4.66, p=0.025) compared with cohort A. Median OSs were not different between the four cohorts. Conclusion: Durvalumab consolidation provided similar benefit in EGFR M+ patients with PD-L1 ≥50% compared with EGFR M- patients. A therapeutic role of durvalumab in patients with EGFR M+, high PD-L1 unresectable stage III NSCLC should be considered.